13Antibiotic-resistant infections are predicted to kill 10 million people worldwide per year 14 by 2050 and to cost the global economy 100 trillion USD. Novel approaches and 15 alternatives to conventional antibiotics are urgently required to combat antimicrobial 16 resistance. We have synthesized a chitosan-based oligolysine antimicrobial peptide, 17 CSM5-K5, which targets multidrug resistant (MDR) bacterial species. Here we show 18 that CSM5-K5 exhibits rapid bactericidal activity against methicillin resistant 19 Staphylococcus aureus (MRSA), MDR Escherichia coli, and vancomycin resistant 20 Enterococcus faecalis (VRE). Combinatorial therapy of CSM5-K5 with antibiotics to 21 which each organism is otherwise resistant restores sensitivity to the conventional 22 antibiotic. CSM5-K5 alone significantly reduced pre-formed bacterial biofilm by two-four 23 orders of magnitude and, in combination with traditional antibiotics, reduced pre-formed 24 biofilm by more than two-three orders of magnitude at sub inhibitory concentrations.
25Moreover, using a mouse excisional wound infection model, CSM5-K5 treatment 26 reduced bacterial burdens by one to three orders of magnitude, and acted 27 synergistically with vancomycin and tetracycline to clear VRE and MDR E. coli, 28 respectively. Importantly, little to no resistance against CSM5-K5 arose for any of the 29 three MDR bacteria during 15 days of serial passage. This work demonstrates the 30 feasibility and benefits of using this synthetic cationic peptide as alternative to, or in 31 combination with, traditional antibiotics to treat infections caused by MDR bacteria. 32 33Antibiotic resistance is a threat to global public health and sustainability (1). Antibiotic 35 resistance currently accounts for an estimated 70,000 annual deaths globally, and in the 36 absence of new therapeutics, infections caused by resistant "superbugs" could kill an 37 additional 10 million people each year worldwide by 2050, surpassing cancer (2). 38 Moreover, by 2050, antibiotic resistant infections are estimated to cost up to 3.5% of the 39 global GDP, equivalent to 100 trillion USD (2). Because corporate antibiotic 40 development pipelines of have progressively declined over the past 20 years (3), there 41 is substantial interest in seeking alternative therapeutic approaches to combat these 42 multidrug resistant (MDR) pathogens. 43 44 Host-derived antimicrobial peptides (CAMPs), typically composed of cationic and 45 hydrophobic domains, have garnered interest as alternative therapies for MDR 46 infections. CAMPs are electrostatically attracted to anionic bacterial cell surfaces, 47followed by peptide insertion into the lipid bilayer via their hydrophobic residues (4, 5).
48Chitosan is a polysaccharide composed of repeating N-glucosamine, with a structure 49 similar to that of bacterial peptidoglycan. This unique feature of chitosan renders it 50 potentially compatible with the bacterial cell wall. Numerous studies have examined the 51 efficacy of chitosan-CAMP hybrids containing quaterna...